August 2009

Contents

Editorial

• Volume 10 Number 7/8 July/August 2009

Special reports

• HIV swine flu triage tools and flowcharts

• HIV and swine flu – patient leaflet

Conference reports

• 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 19-23 July 2009, Cape Town

• Five-year survival rates of 87% without routine CD4 or laboratory monitoring in DART study demonstrate an important model for ARV access programmes

• Biomarkers associated with mortality: long-term follow up from SMART

• Update on Interleukin-2 clinical trials

• Influenza vaccine effective in HIV-positive adults

• Reducing HIV transmission during breastfeeding

• Treating children previously exposed to single dose nevirapine

• 10th International Workshop on Clinical Pharmacology of HIV Therapy, 15-17 April 2009, Amsterdam

• Monotherapy study may explain previous poor clinical results when abacavir and tenofovir are used in combination

• Interactions between ARVs and antimalarials atovaquone and proguanil

• Four weeks lopinavir/r to cover functional monotherapy when stopping HAART

• Efavirenz-related studies: genetics, smoking and TDM

• Atazanavir: a suitable case for TDM?

• Raltegravir PK in blood plasma and the genital tract

• A CYP2B6 haplotype influences nevirapine plasma concentrations following a single dose to reduce mother to child transmission

• Population pharmacokinetic model of nevirapine maternal to infant transfer through breastfeeding

• Phenotypic and genotypic inhibitory quotients and virologic response in treatment experienced children

• Tenofovir pharmacokinetics in three tenofovir-containing regimens in children and adolescents

• Bioavailability of Thai generic lopinavir/ritonavir

• XVIII International Drug Resistance Workshop, 9-13 June 2009, Florida

• Transmitted multidrug-resistant HIV persists in PBMC DNA for years

• Low-level Q148R in people without integrase inhibitor experience

• Cut-offs suggested for predicting efavirenz failure with low-level K103N

• Lower M184V rates with FTC/TDF than with 3TC/TDF

• HBV resistance to lamivudine at undetectable and low levels of viremia

Antiretrovirals

• Raltegravir approved in the US for treatment-naive patients: paranoia and anxiety added as side effects

Guidelines

• UK (BHIVA) guidelines online for comment (2009)

TB coinfection

• TMC207 reduces time to sputum conversion in phase II trial on patients with drug-resistant TB

Basic science and immunology

• Maximum suppression: ART intensification does not reduce residual viral load

• The role of Ad5-specific CD4 T-cells in enhancing risk of HIV acquisition in the Merck vaccine trial

• Tracing HIV reservoirs

• Illuminating early events in HIV infection using single genome amplification

PDFs

• Volume 10 Number 7/8 July/August 2009 PDF